Eli Lilly announced that its Phase 3 BRUIN CLL-322 trial showed adding Jaypirca (pirtobrutinib) to venetoclax and rituximab significantly improved progression-free survival in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The combination reduced the risk of disease progression or death by 45% compared to venetoclax and rituximab alone, with median progression-free survival not reached in the Jaypirca arm versus 39.7 months in the control arm. Benefits were seen across high-risk patient groups, and the company plans to submit these results to global regulators to expand Jaypirca’s approved use. Further Phase 3 studies are ongoing to evaluate the therapy in CLL/SLL.
Eli Lilly announced positive Phase 1 results for AJ1-11095, a novel type II JAK2 inhibitor targeting myelofibrosis patients who failed type I JAK2 inhibitors. The drug demonstrated a strong safety profile, significant spleen size reduction, symptom i...
At the American Diabetes Association conference, leading drugmakers like Eli Lilly and Novo Nordisk showcased new obesity treatments including advanced GLP-1 pills and shots promising greater weight loss and easier dosing schedules. Eli Lilly's exper...
Eli Lilly's stock has surged over 20% recently, driven mainly by two obesity drugs, Mounjaro and Zepbound, but this growth is risky due to heavy reliance on few products and price pressures. Investors are paying high multiples amid peak hype, which m...
Eli Lilly reported a strong Q1 2026 with revenue up 55.5%, driven by its obesity drug Mounjaro and new oral GLP-1 pill Foundayo, raising its full-year guidance. In contrast, Novo Nordisk saw a 4% adjusted sales decline, job cuts, and challenges inclu...
About 30 million Americans use GLP-1 drugs, which chemically suppress appetite and reduce fast food demand by 27-30%. This structural shift benefits companies like Amazon, which is expanding its pharmacy and delivery services; Eli Lilly, leading with...
